Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Journal of Immunotherapy and Precision Oncology is Scopus-indexed (Q2, CiteScore 5.1), WoS ESCI, DOAJ. Published by Innovative Healthcare Institute.
Checked against the index lists dated .
ISSN 2590-017XVerify ISSN ↗2666-2345Verify ISSN ↗
Publisher: Innovative Healthcare Institute
Cost to publish: Checking DOAJ for article charges…
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Oncology | 150 / 428 | 65th | Q2 |
| Immunology and Allergy | 107 / 234 | 54th | Q2 |
| Immunology | 121 / 243 | 50th | Q2 |
| Cancer Research | 123 / 233 | 47th | Q3 |
Not listed in: ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2018–present, best quartile Q2, CiteScore 5.1.
Journal of Immunotherapy and Precision Oncology is Q2 in Oncology (rank 150 of 428), Q2 in Immunology and Allergy (rank 107 of 234) and Q2 in Immunology (rank 121 of 243), by CiteScore 2025. It is ranked in 4 subject areas in all.
Journal of Immunotherapy and Precision Oncology is indexed in the Emerging Sources Citation Index, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 5.1, which places it in quartile Q2 at the 65th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 1.370, quartile Q1, with an H-index of 15.
The publisher lists an article processing charge of about US$2,400 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Journal of Immunotherapy and Precision Oncology is published by Innovative Healthcare Institute. Its print ISSN is 2590-017X and its online ISSN is 2666-2345.
Yes — indexed in the Emerging Sources Citation Index.
Yes — it is an open-access journal, listed in DOAJ.
Journal of Immunotherapy and Precision Oncology has an h-index of 20 and a 2-year mean of 3.06 citations per paper (OpenAlex). Its Scopus CiteScore is 5.1, quartile Q2. On 2-year citations it ranks #109 of 424 Scopus journals in Oncology.
Journal of Immunotherapy and Precision Oncology published 30 papers in 2025; its busiest recent year was 2020 with 40. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 100 research articles (2023–2026), authors are most often from United States (67.8%), Saudi Arabia (5.3%) and United Kingdom (4%). More than half of recent authorship comes from one country.
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. No retracted papers are recorded. The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.